Direct Access to Highly Enantioenriched α-Branched Acrylonitriles through a One-Pot Sequential Asymmetric Michael Addition/Retro-Dieckmann/Retro-Michael Fragmentation Cascade
摘要:
A highly enantioselective synthesis of alpha-branched acrylonitriles is reported featuring a one-pot sequential asymmetric Michael addition/retro-Dieckmann/retro-Michael fragmentation cascade. The method, which relies on a solid, bench-stable, and commercially available acrylonitrile surrogate, is practical, scalable, and highly versatile and provides a direct access to a wide range of enantioenriched nitrite-containing building blocks. Most importantly, the method offers a new tool to incorporate an acrylonitrile moiety in an asymmetric fashion.
N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
申请人:Texas Biotechnology Corp.
公开号:US06342610B2
公开(公告)日:2002-01-29
Thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.
[EN] PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING OR PREVENTING A RESPIRATORY SYNCYTIAL VIRUS INFECTION<br/>[FR] DÉRIVÉS DE PYRIMIDINE ET LEUR UTILISATION DANS LE TRAITEMENT OU LA PRÉVENTION D'UNE INFECTION PAR LE VIRUS RESPIRATOIRE SYNCYTIAL
申请人:REVIRAL LTD
公开号:WO2018025043A1
公开(公告)日:2018-02-08
Pyrimidine derivatives of formula (I) wherein: Z is a direct bond or -(CH2)n- wherein n is 1 or 2; one of X and Y is N, CH or CF, and the other of X and Y is CH; one of R1 and R2 is selected from -NHR, -NR2, -OR, -SR, -S(O)R, -S(O)2R and a group of the following formula (A) and the other of R1 and R2 is selected from -NHR', -OH, -OR' and a group of the above formula (A); R is unsubstituted C1-C6 alkyl; R' is a group selected from C1-C6 alkyl, 5- to 12-membered aryl and C3-C6 cycloalkyl, which group is unsubstituted or substituted; W is -(CH2)m-, -CH2-O-CH2-, -CH2-S-CH2- or -CH2-S(O)2-CH2-; p is 1, q is an integer of 1 - 6 and V is N; or p is 1, q is 0 and V is CH; or p is 0, q is 0 and V is N; r is 0 or 1; and R3 is -(CH2)s-NH2 or -(CH2)s-OH wherein s is 0 or an integer of 1 to 4; and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.
A Simple Nickel Catalyst Enabling an
<i>E</i>
‐Selective Alkyne Semihydrogenation
作者:Niklas O. Thiel、Benyapa Kaewmee、Trung Tran Ngoc、Johannes F. Teichert
DOI:10.1002/chem.201903850
日期:2020.2.3
Stereoselective alkyne semihydrogenations are attractive approaches to alkenes, which are key building blocks for synthesis. With regards to the most atom‐economic reducing agent dihydrogen (H2), only few catalysts for the challenging E‐selectivealkyne semihydrogenation have been disclosed, each with a unique substrate scope profile. Here, we show that a commercially available nickel catalyst facilitates
立体选择性炔烃半氢化是制备烯烃的有吸引力的方法,烯烃是合成的关键组成部分。对于最具原子经济性的还原剂二氢(H 2 ),仅公开了少数用于具有挑战性的E-选择性炔烃半氢化的催化剂,每种催化剂都具有独特的底物范围特征。在这里,我们表明,市售的镍催化剂促进了多种取代内炔的E-选择性炔烃半氢化。这产生了一个简单且广泛适用的整体方案,用于使用 H 2立体选择性地访问E-烯烃,这可以作为通用的合成方法。
Process for the preparation of ethylenic carbonyl compounds
申请人:Rhone-Poulenc Sante
公开号:US04749814A1
公开(公告)日:1988-06-07
Ethylenic carbonyl compounds of formula ##STR1## are made by the isomerization of acetylenic alcohols of formula ##STR2## in the presence of a catalyst consisting of a titanium derivative, a copper or silver derivative, and, if required, an acid, which may be in the form of an ester or anhydride, or an inorganic ester.
There are disclosed compounds of formula (I) ##STR1## and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.